Leonard Post, Ph.D.
Scientific Advisor

Dr. Post is a virologist by training. Most recently, he was at Onyx Pharmaceuticals as SVP and was responsible for the co-development (50:50 with Bayer) of Nexavar from IND through FDA approval for renal cell carcinoma. Previously, as VP of Discovery Research at Parke-Davis he led a multi-national drug discovery organization of over 800 people, in cancer, infectious diseases, inflammation, cardiovascular and CNS. Prior to that, he held several positions at the Upjohn Company, including Director of Infectious Disease Research. During his industry career spanning more than 25 years, he has led numerous programs that have resulted in multiple clinical candidates across various therapeutic areas.

JJ (Kim) Wright, Ph.D.
Scientific Advisor

In 1983 Dr. Wright joined Bristol-Myers as head of the cardiovascular chemistry group. He subsequently was given the additional responsibility for biology in this therapeutic area. He became Vice-president of Chemistry when Bristol-Myers merged with Squibb in 1990, where he was responsible for oncology, antibacterial, antifungal, dermatology, CNS and natural product chemistry programs. In 2001 he left Bristol-Myers Squibb to join ChemoCentryx which focused on chemokine function modulators where, as Senior Vice-President for Chemistry and Preclinical Development, he built the chemistry and drug development functions within the company. At ChemoCentryx, Dr. Wright led the team that brought a novel chemokine antagonist into clinical trials, where it is currently in Phase III. Two other programs initiated during his tenure have also advanced to early clinical evaluation. Dr. Wright retired from ChemoCentryx in late 2006 and moved to Australia to live permanently. He consults for and serves on advisory boards for several biotechnology companies.